Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review

Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Dae Hyun, Yoon, Jai Hoon, Jun, Dae Won, Lee, Oh Young, Yoon, Byung Chul, Lee, Hang Rak, Kim, Kyung Soo, Choi, Ho Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Liver Cancer Association 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035694/
https://www.ncbi.nlm.nih.gov/pubmed/37383059
http://dx.doi.org/10.17998/jlc.20.1.67
Descripción
Sumario:Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumors. Several adverse effects have been reported in the literature; however, cardiotoxicity is rare. We present a case of recurrent coronary vasospasm caused by short-term administration (5 days) of sorafenib. Since it caused refractory ischemia after re-administration, we had no choice but to stop the treatment.

Ejemplares similares